Skip to main content
    R

    Royalty Pharma Plc (RPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.53
    -0.79 (-1.13%)

    Market Cap: $39.85B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Royalty Pharma Plc (RPRX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Royalty Pharma Plc (RPRX) trades at 12.9x trailing earnings and 11.7x sales. Its P/E of 12.9x is above its 5-year median of 8.2x. Its forward P/E is 34.4x. The median P/E across 7 similar companies is 30.0x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 62.5% lower over the next year.

    MultipleValue
    P/E (trailing)12.9x
    Forward P/E34.4x
    Price to sales11.7x
    Price to book4.5x
    EV/EBITDA26.1x
    PEG2.1
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/E12.9x8.2xN/A
    P/S11.7x7.3xN/A
    P/B4.5x2.7xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/E ranged from 5.9x in 2023 to 13.7x in 2021.

    Year endPriceP/EP/SP/B
    2025$38.648.0x7.4x3.3x
    2024$25.516.2x5.4x2.2x
    2023$28.095.9x5.7x2.6x
    2022$39.5210.7x8.0x3.7x
    2021$39.8513.7x7.7x4.2x
    2020$50.058.5x8.6x2.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RPRX

    What is RPRX's forward P/E ratio?

    Royalty Pharma Plc has a forward P/E ratio of 34.4x.

    Is RPRX stock overvalued?

    GNG's valuation label for RPRX is Fairly valued. Its P/E of 12.9x compares with a median of 30.0x across 7 similar companies.

    What is RPRX's price to sales ratio?

    Royalty Pharma Plc has a price to sales ratio of 11.7x.

    What is Royalty Pharma Plc's average P/E ratio over 5 years?

    Royalty Pharma Plc's median P/E over the last 5 years is 8.2x, from 60 month-end values through Oct 2026.

    What is RPRX's PEG ratio?

    Royalty Pharma Plc has a PEG ratio of 2.1.